iData Insights

Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 29, 2016 16:59 IST

Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015, provides an overview of the Complicated Skin And Skin Structure Infections (cSSSI) s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Complicated Skin And Skin Structure Infections (cSSSI) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Complicated Skin And Skin Structure Infections (cSSSI) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Complicated Skin And Skin Structure Infections (cSSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Complicated Skin And Skin Structure Infections (cSSSI) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Complicated Skin And Skin Structure Infections (cSSSI) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Complicated Skin And Skin Structure Infections (cSSSI) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173384/complicated-skin-and-skin-structure-infections-csssi-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173384/complicated-skin-and-skin-structure-infections-csssi-pipeline-review-h2-2015

Table of Contents

Introduction 5

Global Markets Direct Report Coverage 5

Complicated Skin And Skin Structure Infections (cSSSI) Overview 6

Therapeutics Development 7

Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) - Overview 7

Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics under Development by Companies 8

Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Complicated Skin And Skin Structure Infections (cSSSI) - Products under Development by Companies 12

Complicated Skin And Skin Structure Infections (cSSSI) - Companies Involved in Therapeutics Development 13

CrystalGenomics, Inc. 13

Debiopharm International S.A. 14

Dong-A Socio Group 15

GlaxoSmithKline Plc 16

Melinta Therapeutics, Inc 17

MicuRx Pharmaceuticals, Inc. 18

Motif Bio Plc 19

Phosphagenics Limited 20

Complicated Skin and Skin Structure Infections (cSSSI) - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 29

CG-400549 - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Debio-1450 - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Debio-1452 - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

delafloxacin - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

gepotidacin mesylate - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

iclaprim mesylate - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

MRX-I - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecule for Complicated Skin and Skin Structure Infections - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

tedizolid phosphate - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Complicated Skin And Skin Structure Infections (cSSSI) - Recent Pipeline Updates 48

Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects 65

Complicated Skin and Skin Structure Infections (cSSSI) - Product Development Milestones 66

Featured News & Press Releases 66

Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015 66

Sep 03, 2015: FDA Grants Fast Track Designation for Iclaprim 66

Aug 24, 2015: Potent Efficacy of Iclaprim Confirmed in Independent Laboratory Study 67

Apr 30, 2014: Cubist to Present New Pipeline Data Of Tedizolid Phosphate At 2014 European Congress of Clinical Microbiology and Infectious Diseases 67

Oct 22, 2013: Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections 68

Sep 04, 2013: Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug 69

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72

Read More http://www.idatainsights.com/reports-landing-page.php?id=173384/complicated-skin-and-skin-structure-infections-csssi-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects